KRAS G12D Inhibitor HRS-4642: all 21 studies that test it
Page 1 of 1. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy ParticipantsNot yet recruitingNCT07906691Phase 1
- HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic CancerNot yet recruitingNCT07900789Phase 3
- Effect of Itraconazole on the Pharmacokinetics of Intravenous HRS-4642 in Healthy ParticipantsNot yet recruitingNCT07894679Phase 1
- An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid TumorsRecruitingNCT07806058Phase 1/2
- Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic CancerNot yet recruitingNCT07691593Phase 2
- Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingNCT07503639Phase 2
- A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic CancerRecruitingNCT07438106Phase 2
- HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid TumorsRecruitingNCT07296341Phase 1/2
- HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D MutationRecruitingNCT07240766Phase 2
- HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic CancerRecruitingNCT07232875Phase 3
- HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic CancerRecruitingNCT07131514Phase 2
- Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid TumorsNot yet recruitingNCT06955390Phase 1/2
- An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic CancerRecruitingNCT06938282Phase 2
- HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer PatientsRecruitingNCT06770452Phase 2
- A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.RecruitingNCT06620848Phase 2
- HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic CancerRecruitingNCT06587061Phase 2
- Exploratory Platform Research on Precision Therapy of Advanced Pancreatic CancerRecruitingNCT06547736Phase 2
- A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid TumorsRecruitingNCT06520488Phase 1/2
- Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal AdenocarcinomaRecruitingNCT06427239Phase 1/2
- HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT06773130Phase 1/2
- Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D MutationActive, not recruitingNCT05533463Phase 1